[A double-blind comparison between mianserin and imipramine (author's transl)].
Fifty-four depressed patients aged 18 to 65 years were treated for 4 weeks with a daily dose of either 60 mg mianserin or 150 mg imipramine in a double-blind controlled trial. The results which were measured on the Hamilton rating scale, on the Beck and on the Overall rating scale, on the brief psychiatric rating scale (BPRS) and on a global rating scale, did not show any significant difference relative to the antidepressive efficiency of both products. The frequency of side-effects however was significantly lower in the mianserin group than in the imipramine group.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D003984:Dibenzazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
D003984:Dibenzazepines; D008803:Mianserin; D007099:Imipramine
Une comparaison, en double insu, entre mianserine et imipramine.